Patient-specific induced pluripotent stem cell models: Generation and characterization of cardiac cells

Methods in Molecular Biology

Volumn 1353, Issue , 2016, Pages 147-162

  Zanella, Fabian ^a   Sheikh, Farah ^a  

^a NONE

Author keywords

Cardiac assays; Cardiac differentiation; Cardiomyocyte; Human induced pluripotent stem cells; Small molecule; Wnt signaling pathway

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 6 [[2 [[4 (2,4 DICHLOROPHENYL) 5 (4 METHYL 1H IMIDAZOL 2 YL) 2 PYRIMIDINYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; BUFFER; COLLAGENASE; EDETIC ACID; GROWTH FACTOR; LAMININ; ACTININ; AMIDE; BIOLOGICAL MARKER; CALCIUM; COLLAGEN; DRUG COMBINATION; ENZYME INHIBITOR; HOMEODOMAIN PROTEIN; INSULIN; MATRIGEL; NKX2-5 PROTEIN, HUMAN; PROTEOGLYCAN; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR;

CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; DISSOCIATION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; PLURIPOTENT STEM CELL; STEM CELL CULTURE; BIOLOGICAL MODEL; CARDIAC MUSCLE CELL; CELL CULTURE TECHNIQUE; CHEMISTRY; CONGESTIVE CARDIOMYOPATHY; CYTOLOGY; DRUG COMBINATION; DRUG EFFECTS; GENE EXPRESSION; GENETICS; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MOLECULAR IMAGING; NUCLEAR REPROGRAMMING; PATHOLOGY; PRIMARY CELL CULTURE; PROCEDURES;

ACTININ; AMIDES; BIOMARKERS; CALCIUM; CARDIOMYOPATHY, DILATED; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELLULAR REPROGRAMMING; COLLAGEN; DRUG COMBINATIONS; ENZYME INHIBITORS; GENE EXPRESSION; HOMEODOMAIN PROTEINS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; INSULIN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LAMININ; MODELS, BIOLOGICAL; MOLECULAR IMAGING; MYOCYTES, CARDIAC; PRIMARY CELL CULTURE; PROTEOGLYCANS; PYRIDINES; PYRIMIDINES; TRANSCRIPTION FACTORS;

EID: 84946762238     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/7651_2014_172     Document Type: Chapter

References (24)

1. Zanella F, Lyon RC, Sheikh F (2014) Modeling heart disease in a dish: from somatic cells to disease-relevant cardiomyocytes. Trends Cardi-ovasc Med 24(1):32-44. doi:10.1016/j.tcm. 2013.06.002
2. Sharma A, Wu JC, Wu SM (2013) Induced pluripotent stem cell-derived cardiomyocytes for cardiovascular disease modeling and drug screening. Stem Cell Res Ther 4(6):150. doi:10.1186/scrt380
3. Carvajal-Vergara X, Sevilla A, D’Souza SL, Ang YS, Schaniel C, Lee DF, Yang L, Kaplan AD, Adler ED, Rozov R, Ge Y, Cohen N, Edel-mann LJ, Chang B, Waghray A, Su J, Pardo S, Lichtenbelt KD, Tartaglia M, Gelb BD, Lemischka IR (2010) Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome.nature 465 (7299):808-812. doi:10.1038/nature09005,nature09005 [pii]
4. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, Feldman O, Gepstein A, Arbel G, Hammerman H, Boulos M, Gep-stein L (2011) Modelling the long qT syndrome with induced pluripotent stem cells.nature 471(7337):225-229. doi:10.1038/nature09747
5. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L, Dorn T, Goedel A, Hohnke C, Hofmann F, Seyfarth M, Sinnecker D, Schomig A, Laugwitz KL (2010) Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 363 (15):1397-1409. doi:10.1056/NEJMoa0908679,NEJMoa0908679[pii]
6. Lahti AL, Kujala VJ, Chapman H, Koivisto AP, Pekkanen-Mattila M, Kerkela E, Hyttinen J, Kontula K, Swan H, Conklin BR, Yamanaka S, Silvennoinen O, Aalto-Setala K (2012) Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech 5(2):220-230. doi:10.1242/dmm.008409
7. Matsa E, Rajamohan D, Dick E, Young L, Mellor I, Staniforth A, Denning C (2011) Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J 32(8):952-962. doi:10.1093/eurheartj/ehr073
8. Yazawa M, Hsueh B, Jia X, Pasca AM, Bernstein JA, Hallmayer J, Dolmetsch RE (2011) Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome.nature 471(7337):230-234. doi:10.1038/nature09855
9. Itzhaki I, Maizels L, Huber I, Gepstein A, Arbel G, Caspi O, Miller L, Belhassen B, Nof E, Glikson M, Gepstein L (2012) Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. J Am Coll Cardiol 60(11):990-1000. doi:10.1016/j.jacc.2012.02.066
10. Fatima A, Xu G, Shao K, Papadopoulos S, Lehmann M, Arnaiz-Cot JJ, Rosa AO, Nguemo F, Matzkies M, Dittmann S, Stone SL, Linke M, Zechner U, Beyer V, Hennies HC, Rosenkranz S, Klauke B, Parwani AS, Haverkamp W, Pfitzer G, Farr M, Cleemann L, Morad M, Milting H, Hescheler J, Saric T (2011) In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. Cell Physiol Biochem 28(4):579-592. doi:10.1159/000335753
11. Jung CB, Moretti A, Mederos y Schnitzler M, Iop L, Storch U, Bellin M, Dorn T, Rup-penthal S, Pfeiffer S, Goedel A, Dirschinger RJ, Seyfarth M, Lam JT, Sinnecker D, Guder-mann T, Lipp P, Laugwitz KL (2012) Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catechol-aminergic polymorphic ventricular tachycardia. EMBO Mol Med 4(3):180-191. doi:10.1002/emmm.201100194
12. Kujala K, Paavola J, Lahti A, Larsson K, Pekkanen-Mattila M, Viitasalo M, Lahtinen AM, Toivonen L, Kontula K, Swan H, Laine M, Silvennoinen O, Aalto-Setala K (2012) Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed after depolarizations. PLoS One 7(9):e44660. doi:10.1371/journal.pone.0044660
13. Sun N, Yazawa M, Liu J, Han L, Sanchez-Freire V, Abilez OJ, Navarrete EG, Hu S, Wang L, Lee A, Pavlovic A, Lin S, Chen R, Hajjar RJ, Snyder MP, Dolmetsch RE, Butte MJ, Ashley EA, Longaker MT, Robbins RC, Wu JC (2012) Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med 4(130):130-147. doi:10.1126/scitranslmed.3003552
14. Lan F, Lee AS, Liang P, Sanchez-Freire V, Nguyen PK, Wang L, Han L, Yen M, Wang Y, Sun N, Abilez OJ, Hu S, Ebert AD, Navarrete EG, Simmons CS, Wheeler M, Pruitt B, Lewis R, Yamaguchi Y, Ashley EA, Bers DM, Robbins RC, Longaker MT, Wu JC (2013) Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 12(1):101-113. doi:10.1016/j.stem.2012.10.010
15. Han L, Li Y, Tchao J, Kaplan AD, Lin B, Li Y, Mich-Basso J, Lis A, Hassan N, London B, Bett GC, Tobita K, Rasmusson RL, Yang L (2014) Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells. Cardiovasc Res 104:258. doi:10.1093/cvr/cvu205
16. Ma D, Wei H, Lu J, Ho S, Zhang G, Sun X, Oh Y, Tan SH, Ng ML, Shim W, Wong P, Liew R (2012) Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 34:1122. doi:10.1093/eurheartj/ehs226
17. Kim C, Wong J, Wen J, Wang S, Wang C, Spiering S, Kan NG, Forcales S, Puri PL, Leone TC, Marine JE, Calkins H, Kelly DP, Judge DP, Chen HS (2013) Studying arrhyth-mogenic right ventricular dysplasia with patient-specific iPSCs. nature 494:105. doi:10.1038/nature11799
18. Caspi O, Huber I, Gepstein A, Arbel G, Maizels L, Boulos M, Gepstein L (2013) Modeling of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells. Circ Cardiovasc Genet 6(6):557-568. doi:10.1161/CIRCGENETICS.113.000188
19. Davis RP, Casini S, van den Berg CW, Hoekstra M, Remme CA, Dambrot C, Salvatori D, Oostwaard DW, Wilde AA, Bezzina CR, Verkerk AO, Freund C, Mummery CL (2012) Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation 125(25):3079-3091. doi:10.1161/CIRCULATI0NAHA.111.066092
20. Lian X, Zhang J, Azarin SM, Zhu K, Hazeltine LB, Bao X, Hsiao C, Kamp TJ, Palecek SP (2013) Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/beta-catenin signaling under fully defined conditions. Nat Protoc 8(1):162-175. doi:10.1038/nprot.2012.150
21. Burridge PW, Matsa E, Shulda P, Lin ZC, Churko JM, Ebert AD, Lan F, Diecke S, Huber B, Mordwinkin NM, Plews JR, Abilez OJ, Cui B, Gold JD, Wu JC (2014) Chemically defined generation of human cardiomyocytes. Nat Methods 11(8):855-860. doi:10.1038/nmeth.2999
22. Chen G, Gulbranson DR, Hou Z, Bolin JM, Ruotti V, Probasco MD, Smuga-Otto K, Howden SE, Diol NR, Propson NE, Wagner R, Lee GO, Antosiewicz-Bourget J, Teng JM, Thomson JA (2011) Chemically defined conditions for human iPSC derivation and culture. Nat Methods 8(5):424-429. doi:10.1038/nmeth.1593
23. Lian X, Hsiao C, Wilson G, Zhu K, Hazeltine LB, Azarin SM, Raval KK, Zhang J, Kamp TJ, Palecek SP (2012) Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci USA 109(27):E1848-E1857. doi:10.1073/pnas.1200250109
24. Lian X, Zhang J, Zhu K, Kamp TJ, Palecek SP (2013) Insulin inhibits cardiac mesoderm, not mesendoderm, formation during cardiac differentiation of human pluripotent stem cells and modulation of canonical Wnt signaling can rescue this inhibition. Stem Cells 31(3):447-457. doi:10.1002/stem.1289